ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Partner program
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,937 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical IndustryAllschwilBasilea Pharmaceutica International AG, Allschwil
Basilea Pharmaceutica International AG, Allschwil Logo
Verified· 3 sourcesTrust Score
Summary

About the company

Basilea Pharmaceutica International AG, Allschwil develops and commercializes pharmaceutical products focused on anti-infectives, particularly antifungal and antibiotic therapies. The company’s portfolio includes Cresemba (isavuconazole) and Zevtera (ceftobiprole), and it maintains clinical and preclinical programs for additional anti-infective candidates.

AI-generated
Offering

Products & services

Industry:Pharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4.2/5

Basilea Pharmaceutica International AG, Allschwil

✓ Offered9
Development and commercialization of anti-infectives
Development and commercialization of innovative medicines in the anti-infectives area, focusing on antimycotics and antibiotics from research through to commercialization.
Antimycotics
Antimycotics for invasive fungal infections, including intravenous and oral treatments for invasive aspergillosis, mucormycosis and invasive candidiasis.
Antibiotics
Antibiotics for severe bacterial infections, in particular pneumonia, Staphylococcus aureus bacteremia, acute skin and soft tissue infections, and complicated urinary tract infections.
Cresemba (Isavuconazole)
Intravenous and oral antifungal for invasive aspergillosis and mucormycosis; marketed worldwide in many countries through license and distribution agreements.
Zevtera (Ceftobiprole)
Intravenous antibiotic for the treatment of pneumonia; in the US also approved for Staphylococcus aureus bacteremia, acute bacterial skin infections and community-acquired pneumonia.
Fosmanogepix
Clinical broad-spectrum antimycotic candidate in an intravenous and oral formulation, in Phase 2 and Phase 3 studies for candidemia and invasive fungal infections.
BAL2062
Clinical antimycotic candidate with a new mechanism of action against invasive mold infections; evaluated in a completed Phase 1 study.
Ceftibuten-ledaborbactam etzadroxil
Oral BL/BLI combination candidate with ceftibuten and ledaborbactam etzadroxil; in development for complicated urinary tract infections and not yet approved.
BAL2420 (LptA inhibitor)
Antibiotic development candidate against Gram-negative bacteria, with the first clinical study on safety, tolerability and pharmacokinetics in healthy adults.
Trust & reputation

ranQ Trust Score of Basilea Pharmaceutica International AG, Allschwil: 4.2 out of 5.0

Trust Score4.2/ 5.0

Very high

x

Data basis 96% · As of October 2026

Basilea Pharmaceutica International AG, Allschwil scores 59.6 out of 100 points in the Reputation area of the ranQ Trust Score. This area carries 42% of the weighting.
x
CriterionValueWeight
  • Review quality: The average rating across all connected sources, smoothed against the industry mean. So 5.0 stars from three reviews do not outrank 4.7 from three hundred.66.724%
  • Review volume: The number of reviews across all sources. The scale is logarithmic: the first reviews count the most, and the maximum is reached at 50 reviews.27.910%
  • Review recency: The age of the most recent review. Two-year-old reviews deliberately sit in the middle, because that is normal for Swiss SMEs. Only after three years without a new voice does the value drop markedly.78.08%
Basilea Pharmaceutica International AG, Allschwil scores 95.8 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.100.012%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.96.07%
Basilea Pharmaceutica International AG, Allschwil scores 85.0 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).85.022%
Basilea Pharmaceutica International AG, Allschwil scores 100.0 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.100.04%
  • Media authority: No data point — the criterion is taken out of the weighting and does not lower the score.—4%
Qualifications+0.00

Basilea Pharmaceutica International AG, Allschwil reaches a ranQ Trust Score of 4.2 out of 5.0 — rated «Very high». The rating draws, among other things, on 4.5 out of 5 stars from 2 customer reviews. The data basis is 96%, so the score is backed by part of the criteria. As of October 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Reviews

Aggregated rating

Aggregated rating
4.5
of 5

Aggregated from 2 reviews across all connected sources

Sources
GGoogle4.52
★TrustpilotSoon
PProvenExpertSoon

Further sources are added continuously and factored into the ranQ Rating.

Knowledge

No knowledge articles yet

Once Basilea Pharmaceutica International AG, Allschwil has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Basilea Pharmaceutica International AG, Allschwil in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Basilea Pharmaceutica International AG, Allschwil by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Basilea Pharmaceutica International AG, Allschwil to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Hegenheimermattweg 167b
4123 Allschwil
Opening hours
Mon
08:00 - 12:00, 13:00 - 17:00
Tue
08:00 - 12:00, 13:00 - 17:00
Wed
08:00 - 12:00, 13:00 - 17:00
Thu
08:00 - 12:00, 13:00 - 17:00
Fri
08:00 - 12:00, 13:00 - 17:00
Sat
Closed
Sun
Closed

At a glance

Legal form
Corporation
UID
CHE-114.147.271
Founded
2008 · 18 years
Last commercial register change
July 9, 2025
Employees
101 to 500
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.100.06%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    BP
    Bright Peak Therapeutics AG
    Allschwil
    IP
    Idorsia Pharmaceuticals Ltd
    Allschwil
    PT
    Palto Therapeutics AG
    Allschwil
    MG
    MiHKAL GmbH
    Allschwil
    NS
    Neurocrine Switzerland GmbH
    Allschwil
    BW
    Blue Wave Therapeutics GmbH
    Allschwil
    IT
    Ilonov Therapeutics SA
    Allschwil
    CT
    CAPTOR THERAPEUTICS GmbH
    Allschwil